Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson

Apr 7, 2017
by Dave Williamson
The Market Is Wrong About Vertex

Apr 7, 2017
by Dave Williamson
Don't Sell Amarin Short

Apr 7, 2017
by Dave Williamson
Is it Time to Buy 2012's Worst Biotechs?

Apr 7, 2017
by Dave Williamson
Invest in the Market's Hottest Sector

Apr 7, 2017
by Dave Williamson
Dow Health Care Smackdown

Apr 7, 2017
by Dave Williamson
Will These 3 Health-Care Doubles Keep Going?

Apr 7, 2017
by Dave Williamson
Will These 3 Health-Care Doubles Keep Running?

Apr 7, 2017
by Dave Williamson
Is Chelsea A Bad News Buy?

Apr 7, 2017
by Dave Williamson
2012's 2 Best Health-Care Stocks

Apr 7, 2017
by Dave Williamson
Attention, Investors: It's Time to Sell

Apr 7, 2017
by Dave Williamson
Is Dendreon's Downgrade Deserved?

Apr 7, 2017
by Dave Williamson
Is This Biotech's Best Stock?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.